“`html
PacBio (PACB) has partnered with EpiCypher to enhance epigenomics research using its Fiber-Seq workflow, combining long-read sequencing technology with chromatin biology expertise. This strategic collaboration aims to improve insights into genome regulation and disease mechanisms.
The partnership introduced the CUTANA Hia5 enzyme for Fiber-Seq assays on PacBio’s HiFi sequencing systems, allowing researchers to study chromatin biology at single-molecule resolution. Currently, PACB’s shares are priced at $1.24, with a market capitalization of $378.5 million, amid a year-to-date decline of 32.3%.
The global epigenetics market is projected to grow from $14.63 billion in 2023 to $39.15 billion by 2030, indicating a significant opportunity for PacBio as demand for deeper biological insights increases.
“`
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
